Table 3. Essential Characteristics of Anti-SARS-CoV 2 Virus NP and SARS NP Antibodies.

Epitope Group	BMR Cat No.	Clone No.	Mouse Ig Isotype	Reactivity in CELIXSYS* method (%)			Ag-ELISA method (A490nm)												Epitope analysis based on antibody inhibition test on Ag-ELISA method					
							Nucleo proteins (NP) of SARS-CoV-2 variants or related Corona viruses												Inhibitiion ratio to each biotinylated antibody in %					
				Recombinant WT SARS-CoV-2 NP (Full length)		Native SARS CoV-2 NP	SARS-CoV-2 NP Full length	B.1.1.7 α SARS-CoV-2 NP Variant D3L, R203K, G204R, S235F	B.1.617.2 δ SARS-CoV-2 NP D63G, R203M, D377Y	B.1.1.529 ο SARS-CoV-2 NP P13L, ERS 31-33 deletion, R203K, D204R	SARS - CoV-2 NP 180-418aa	SARS NP	MERS NP	OC43 NP	HKU1 NP	229E NP	NL63 NP	His-tag	S2N2-1898	S2N4-884	S2N4-434	S2N2-572	S2N3-1014	S2N4-6
				Ab Conc. 10ug/mL	Ab Conc. 1ug/mL	C.sup X1	Ab Conc. =1ug/mL												Ab Conc. =1ug/mL					
A	BMRnp101	**S2N2-1710**	IgG1	99	98	62	3.337	2.658	3.368	3.382	0.049	0.063	0.048	0.058	0.073	0.090	0.094	0.075	97	85	23	12	1	28
	BMRnp103	**S2N2-1898**	IgG1	99	94	68	3.272	2.859	3.586	3.512	0.075	0.046	0.045	0.055	0.147	0.076	0.080	0.074	96	78	25	15	4	27
	BMRnp109	**S2N4-294**	IgG1	99	81	68	3.389	2.609	2.915	3.447	0.049	0.136	0.080	0.090	0.180	0.059	0.068	0.085	93	79	18	8	0	7
B	BMRnp111	**S2N4-434**	IgG1	96	86	66	3.242	2.726	3.167	3.433	0.060	0.062	0.050	0.052	0.068	0.071	0.062	0.073	72	35	93	11	2	5
	BMRnp115	**S2N4-1121**	IgG1	97	87	73	3.209	2.781	3.356	3.433	0.052	0.073	0.070	0.055	0.049	0.087	0.052	0.071	76	43	94	23	9	10
C	BMRnp106	**S2N3-2009**	IgG1	97	78	74	3.571	2.459	3.431	3.245	0.087	0.071	0.047	0.085	0.118	0.122	0.079	0.093	59	27	29	18	0	93
	BMRnp110	**S2N4-309**	IgG1	97	96	77	3.534	2.876	3.290	3.487	0.053	0.049	0.049	0.070	0.075	0.067	0.072	0.081	81	33	18	16	0	12
	BMRnp112	**S2N4-555**	IgG1	97	92	58	3.350	2.080	3.115	2.868	0.060	0.059	0.047	0.054	0.081	0.064	0.059	0.076	66	31	22	6	6	12
	BMRnp102	**S2N2-1817**	IgG1	98	93	64	3.439	2.437	3.406	3.250	0.057	0.220	0.045	0.127	0.119	0.074	0.077	0.080	59	15	20	7	6	18
	BMRnp107	**S2N4-264**	IgG1	96	90	64	3.439	2.030	3.043	2.903	0.052	0.047	0.046	0.066	0.062	0.052	0.060	0.074	62	38	24	26	2	21
	BMRnp117	**S2N4-1262**	IgG2a	98	95	71	3.927	3.571	3.758	3.718	0.051	0.074	0.059	0.055	0.141	0.086	0.064	0.081	56	32	14	11	1	15
	BMRnp116	**S2N4-1186**	IgG2a	97	73	70	3.916	3.542	3.775	3.724	0.052	0.329	0.069	0.053	0.265	0.068	0.064	0.082	35	22	21	15	3	16
D	**BMRnp218**	**S2N4-1324**	IgG1	98	89	74	3.299	2.399	3.515	3.389	1.361	0.121	0.049	0.064	0.069	0.066	0.057	0.071	77	34	95	20	3	9
E	BMRnp202	**S2N2-572**	IgG1	98	80	66	2.852	1.874	2.926	3.184	3.700	0.048	0.052	0.047	0.079	0.058	0.066	0.070	6	0	7	82	0	5
	BMRnp210	**S2N4-839**	IgG2b	87	89	77	3.520	3.328	3.560	3.546	3.543	0.086	0.051	0.050	0.095	0.058	0.067	0.072	16	9	22	69	0	3
	BMRnp209	**S2N4-495**	IgG2b	98	95	77	3.546	3.367	3.515	3.662	3.775	0.072	0.052	0.057	0.166	0.063	0.068	0.083	0	5	2	61	5	2
	BMRnp206	**S2N3-104**	IgG2a	99	92	75	3.542	3.207	3.543	3.710	3.884	0.065	0.058	0.050	0.070	0.095	0.060	0.075	4	5	7	67	2	4
	BMRnp214	**S2N4-1198**	IgG2a	100	90	77	3.517	2.916	3.743	3.670	4.000	0.073	0.046	0.065	0.077	0.063	0.062	0.073	6	4	4	58	0	3
F	BMRnp207	**S2N3-1014**	IgG2a	97	96	76	3.871	3.866	3.706	3.890	3.905	0.097	0.062	0.058	0.088	0.106	0.069	0.075	0	4	14	35	88	10
	BMRnp212	**S2N4-1098**	IgG2a	97	97	73	3.902	3.856	3.894	3.910	3.754	0.111	1.463	0.051	0.225	0.055	0.072	0.074	15	7	16	30	87	11
	BMRnp215	**S2N4-508**	IgG1	97	96	70	3.778	3.307	3.791	3.772	4.000	0.068	0.326	0.054	0.209	0.101	0.072	0.080	5	0	9	30	86	6
	BMRnp211	**S2N4-927**	IgG1	97	96	68	3.786	3.648	3.784	3.771	3.647	0.109	0.213	0.051	0.230	0.054	0.060	0.069	7	6	16	25	85	9
	BMRnp217	**S2N4-1237**	IgG1	96	96	67	3.660	3.387	3.707	3.664	3.849	0.170	0.071	0.067	0.175	0.081	0.088	0.093	21	10	12	20	84	6
G	BMRnp203	**S2N2-1565**	IgG1	100	99	76	3.375	3.708	3.630	3.799	3.843	0.124	0.067	0.049	0.085	0.048	0.057	0.068	4	3	12	10	4	7
	BMRnp201	**S2N1-1886**	IgG1	98	22	70	0.366	1.284	2.979	2.320	3.491	0.078	0.052	0.049	0.071	0.063	0.067	0.079	0	6	6	14	0	0
	BMRnp204	**S2N2-1882**	IgG2a	100	99	80	3.834	3.882	3.831	3.918	3.925	0.315	0.057	0.051	0.201	0.054	0.067	0.070	7	1	7	10	5	10
	BMRnp205	**S2N2-2149**	IgG1	99	97	75	3.403	3.301	0.066	3.657	3.830	0.116	0.096	0.048	0.135	0.077	0.061	0.080	11	5	14	23	4	7
	BMRnp208	**S2N3-2158**	IgG1	99	95	81	2.305	1.907	2.863	2.854	3.721	0.062	0.058	0.050	0.183	0.078	0.064	0.087	0	4	3	15	0	0
	BMRnp213	**S2N3-235**	IgG2a	100	98	72	3.179	2.570	3.751	3.508	3.980	0.090	0.056	0.059	0.076	0.083	0.071	0.083	11	2	7	21	0	3
H	BMRnp3108	**S2N4-268**	IgG1	100	98	72	3.480	3.177	3.648	3.613	0.051	1.368	0.047	0.065	0.074	0.072	0.067	0.074	97	90	20	22	5	20
	BMRnp3113	**S2N4-834**	IgG1	100	100	75	3.524	3.234	3.667	3.634	0.065	2.052	0.094	0.088	0.173	0.057	0.062	0.082	99	97	23	17	7	25
	BMRnp3114	**S2N4-884**	IgG2a	100	100	79	3.816	3.801	3.837	3.876	0.082	2.399	0.082	0.072	0.212	0.095	0.071	0.074	99	96	21	23	8	29
	BMRnp307	**S2N4-26**	IgG1	100	100	75	3.481	3.010	3.694	3.644	0.053	3.285	0.068	0.073	0.049	0.092	0.063	0.070	100	98	21	14	5	23
I	BMRnp302	**S2N2-598**	IgG2a	97	89	64	3.820	3.776	3.829	3.848	0.047	4.000	0.074	0.046	0.211	0.147	0.057	0.076	0	11	94	21	4	55
	BMRnp303	**S2N2-789**	IgG1	98	93	62	3.485	3.258	3.584	3.658	0.054	3.925	0.101	0.050	0.069	0.065	0.057	0.074	0	10	95	15	3	28
J	BMRnp305	**S2N4-6**	IgG2a	96	95	68	3.765	3.734	3.758	3.774	0.063	3.844	0.057	0.057	0.064	0.068	0.076	0.079	42	20	21	9	6	89
	BMRnp312	**S2N4-522**	IgG2a	98	95	74	3.778	3.674	3.788	3.793	0.086	3.873	0.059	0.082	0.084	0.086	0.066	0.092	32	17	16	11	0	89
	BMRnp314	**S2N4-726**	IgG1	94	94	71	3.439	2.479	3.492	3.433	0.055	3.474	0.049	0.051	0.056	0.055	0.068	0.070	48	18	22	12	0	88
	BMRnp310	**S2N4-277**	IgG1	97	95	74	3.417	2.507	3.580	3.469	0.048	3.769	0.092	0.049	0.048	0.076	0.058	0.070	45	14	21	18	2	85
K	BMRnp304	**S2N2-1736**	IgG2a	72	20	60	3.834	3.826	3.833	3.833	0.070	4.000	0.059	0.063	0.153	0.078	0.078	0.084	0	4	11	9	1	6
	BMRnp315	**S2N4-1094**	IgG1	98	94	73	3.335	1.824	3.437	3.183	0.064	3.442	0.051	0.077	0.098	0.073	0.063	0.067	75	25	18	14	0	10
	BMRnp301	**S2N1-1211**	IgG1	85	67	62	2.790	2.109	1.764	3.079	0.073	1.965	0.053	0.052	0.236	0.063	0.060	0.072	63	42	42	18	6	9
	BMRnp317	**S2N4-1467**	IgG1	87	70	68	3.102	2.166	3.168	3.013	0.069	3.467	0.066	0.049	0.066	0.122	0.065	0.066	30	12	12	2	1	51

* The CELIXSYS method is an immuno-precipitation-equivalent method. The figure represents the strength of reactivity of monoclonal antibodies to each SARS-CoV-2 virus nucleoprotein.
The higher the figure, the stronger the reactivity of the antibody.

Catalog numbers in purple have changed catalog numbers in January 2023.

Catalog numbers in red are clones newly added in January 2023.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody

＊Contact us for matching pairs

Product Name	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody
BMR Catalog No.	**BMRnp101**	**BMRnp102**	**BMRnp103**	**BMRnp106**	**BMRnp107**	**BMRnp109**	**BMRnp110**	**BMRnp111**
Clone Number	**S2N2-1710**	**S2N2-1817**	**S2N2-1898**	**S2N3-2009**	**S2N4-264**	**S2N4-294**	**S2N4-309**	**S2N4-434**
Lot Number	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot
Isotype	IgG1	IgG1	IgG1	IgG1	IgG1	IgG1	IgG1	IgG1
Concentration	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)
Host	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites
Immunogen	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)
Specificity	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.
Cross Reactivity	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP. However, slight cross-reactivity with SARS-CoV NP recombinant protein was confirmed.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.
Grade & Purity	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).
Form & Buffer	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4
Storage	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃
Method of Purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification
Size	1mg 〜	1mg 〜	1mg 〜	1mg 〜	1mg 〜	1mg 〜	1mg 〜	1mg 〜
Contaminants	NA	NA	NA	NA	NA	NA	NA	NA
Preservative	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3
Biohazard Information	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody

＊Contact us for matching pairs

Product Name	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody
BMR Catalog No.	**BMRnp112**	**BMRnp115**	**BMRnp116**	**BMRnp117**	**BMRnp201**	**BMRnp202**	**BMRnp203**	**BMRnp204**
Clone Number	**S2N4-555**	**S2N4-1121**	**S2N4-1186**	**S2N4-1262**	**S2N1-1886**	**S2N2-572**	**S2N2-1565**	**S2N2-1882**
Lot Number	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot
Isotype	IgG1	IgG1	IgG2a	IgG2a	IgG1	IgG1	IgG1	IgG2a
Concentration	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)
Host	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites
Immunogen	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)
Specificity	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.
Cross Reactivity	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-229E NP and HCoV-NL63 NP. However, slight cross-reactivity with SARS-CoV NP and HCoV-HKU1 NP recombinant protein was confirmed.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-229E NP and HCoV-NL63 NP. However, slight cross-reactivity with SARS-CoV NP and HCoV-HKU1 NP recombinant protein was confirmed.
Grade & Purity	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).
Form & Buffer	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4
Storage	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃
Method of Purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification
Size	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～
Contaminants	NA	NA	NA	NA	NA	NA	NA	NA
Preservative	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3
Biohazard Information	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody

＊Contact us for matching pairs

Product Name	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody
BMR Catalog No.	**BMRnp205**	**BMRnp206**	**BMRnp207**	**BMRnp208**	**BMRnp209**	**BMRnp210**	**BMRnp211**	**BMRnp212**
Clone Number	**S2N2-2149**	**S2N3-104**	**S2N3-1014**	**S2N3-2158**	**S2N4-495**	**S2N4-839**	**S2N4-927**	**S2N4-1098**
Lot Number	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot
Isotype	IgG1	IgG2a	IgG2a	IgG1	IgG2b	IgG2b	IgG1	IgG2a
Concentration	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)
Host	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites
Immunogen	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)
Specificity	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.
Cross Reactivity	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, HCoV-OC43 NP, HCoV-229E NP and HCoV-NL63 NP. However, slight cross-reactivity with MERS-CoV NP and HCoV-HKU1 NP recombinant protein was confirmed.	Cross-reactivity with MERS-CoV NP recombinant protein was confirmed. Slight cross-reactivity with HCoV-HKU1 NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of SARS-CoV NP, HCoV-OC43 NP, HCoV-229E NP and HCoV-NL63 NP.
Grade & Purity	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).
Form & Buffer	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4
Storage	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃
Method of Purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification
Size	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～
Contaminants	NA	NA	NA	NA	NA	NA	NA	NA
Preservative	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3
Biohazard Information	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody

＊Contact us for matching pairs

Product Name	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody
BMR Catalog No.	**BMRnp213**	**BMRnp214**	**BMRnp215**	**BMRnp217**	**BMRnp218**	**BMRnp301**	**BMRnp302**	**BMRnp303**
Clone Number	**S2N3-235**	**S2N4-1198**	**S2N4-508**	**S2N4-1237**	**S2N4-1324**	**S2N1-1211**	**S2N2-598**	**S2N2-789**
Lot Number	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot
Isotype	IgG2a	IgG2a	IgG1	IgG1	IgG1	IgG1	IgG2a	IgG1
Concentration	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)
Host	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites
Immunogen	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)
Specificity	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.
Cross Reactivity	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, HCoV-OC43 NP, HCoV-229E NP and HCoV-NL63 NP. However, slight cross-reactivity with MERS-CoV NP and HCoV-HKU1 NP recombinant protein was confirmed.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. Slight cross-reactivity with HCoV-HKU1 NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. Slight cross-reactivity with HCoV-HKU1 NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.
Grade & Purity	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).
Form & Buffer	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4
Storage	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃
Method of Purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification
Size	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～
Contaminants	NA	NA	NA	NA	NA	NA	NA	NA
Preservative	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3
Biohazard Information	This product contains 0.13% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.13% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.13% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.13% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.13% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody

＊Contact us for matching pairs

Product Name	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody
BMR Catalog No.	**BMRnp304**	**BMRnp305**	**BMRnp307**	**BMRnp310**	**BMRnp312**	**BMRnp314**	**BMRnp315**	**BMRnp3108**
Clone Number	**S2N2-1736**	**S2N4-6**	**S2N4-26**	**S2N4-277**	**S2N4-522**	**S2N4-726**	**S2N4-1094**	**S2N4-268**
Lot Number	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot
Isotype	IgG2a	IgG2a	IgG1	IgG1	IgG2a	IgG1	IgG1	IgG1
Concentration	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)
Host	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites
Immunogen	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)
Specificity	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.
Cross Reactivity	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.
Grade & Purity	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).
Form & Buffer	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4
Storage	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃
Method of Purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification
Size	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～	1mg ～
Contaminants	NA	NA	NA	NA	NA	NA	NA	NA
Preservative	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3
Biohazard Information	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.07% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.09% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.11% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.12% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody

＊Contact us for matching pairs

Product Name	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody	Anti-SARS-CoV-2 NP Monoclonal Antibody
BMR Catalog No.	**BMRnp3113**	**BMRnp3114**	**BMRnp317**
Clone Number	**S2N4-834**	**S2N4-884**	**S2N4-1467**
Lot Number	Depend on the purification Lot	Depend on the purification Lot	Depend on the purification Lot
Isotype	IgG1	IgG2a	IgG1
Concentration	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)	1 ~ 5 mg/mL Depend on the purification Lot (5mg/mL for most lots)
Host	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites	Host : Mouse. Hybridization of P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice. Source : Ascites
Immunogen	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)	SARS-CoV-2 NP (Recombinant)
Specificity	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.	SARS-CoV-2 NP (full length) recombinant protein.
Cross Reactivity	No cross-reactivity with recombinant proteins of SARS-CoV NP, MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.	Cross-reactivity with SARS-CoV NP recombinant protein was confirmed. No cross-reactivity with recombinant proteins of MERS-CoV NP, HCoV-OC43 NP, HCoV-HKU1 NP, HCoV-229E NP and HCoV-NL63 NP.
Grade & Purity	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).	In vitro use only. Purity is more than 95% (SDS-PAGE or HPLC).
Form & Buffer	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4	Protein A affinity purified and supplied as a liquid in PBS(-); pH7.4, 3.0mM KCl, 1.5mM KH2PO4, 140mM NaCl, 8.0mM Na2HPO4
Storage	Store at 2-8℃	Store at 2-8℃	Store at 2-8℃
Method of Purification	Protein A affinity purification	Protein A affinity purification	Protein A affinity purification
Size	1mg ～	1mg ～	1mg ～
Contaminants	NA	NA	NA
Preservative	0.05% NaN_3	0.05% NaN_3	0.05% NaN_3
Biohazard Information	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.05% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.	This product contains 0.13% sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling.